Foravirumab

Foravirumab^?
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	rabies virus glycoprotein
Clinical data
Identifiers
CAS Registry Number	944548-38-3^N
ATC code	None
UNII	377VY97V7S^Y
ChEMBL	CHEMBL1743021^N
Chemical data
Formula	C₆₄₀₀H₉₉₁₄N₁₇₁₈O₁₉₉₈S₄₄
Molecular mass	144.3 kDa
N (what is this?) (verify)

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.^[1] It is under development by Sanofi/Crucell.^[2]

References

↑ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
↑ Khardori, Nancy Misri (2011). Biologic Response Modifiers in Infectious Diseases, An Issue of Infectious Disease Clinics. London: Elsevier Health Sciences. p. 158. ISBN 9781455712076.

Monoclonal antibodies for infectious disease and toxins

Fungal ("-fung-")

Human ("-fungu-")	Efungumab

Viral ("-vi(r)-")

Human ("-viru-")	Exbivirumab Foravirumab Libivirumab Rafivirumab Regavirumab Sevirumab Tuvirumab

Humanized ("-vizu-")	Felvizumab Motavizumab Palivizumab Suvizumab

Bacterial ("-ba(c)-")

Human ("-bacu-")	Nebacumab Panobacumab Raxibacumab

Mouse ("-baco-")	Edobacomab

Chimeric ("-baxi-")	Pagibaximab

Humanized ("-bazu-")	Tefibazumab^†

Toxin ("-tox(a)-")

Human ("-toxu-")	Actoxumab Bezlotoxumab

Humanized ("-toxazu-")	Urtoxazumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III